GYRE
Price
$7.10
Change
-$0.12 (-1.66%)
Updated
Jul 21 closing price
Capitalization
643.66M
28 days until earnings call
MIST
Price
$1.49
Change
-$0.09 (-5.70%)
Updated
Jul 21 closing price
Capitalization
126.6M
15 days until earnings call
Interact to see
Advertisement

GYRE vs MIST

Header iconGYRE vs MIST Comparison
Open Charts GYRE vs MISTBanner chart's image
Gyre Therapeutics
Price$7.10
Change-$0.12 (-1.66%)
Volume$59.44K
Capitalization643.66M
Milestone Pharmaceuticals
Price$1.49
Change-$0.09 (-5.70%)
Volume$1.74M
Capitalization126.6M
GYRE vs MIST Comparison Chart in %
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. MIST commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a StrongBuy and MIST is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (GYRE: $7.10 vs. MIST: $1.49)
Brand notoriety: GYRE and MIST are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 22% vs. MIST: 108%
Market capitalization -- GYRE: $643.66M vs. MIST: $126.6M
GYRE [@Biotechnology] is valued at $643.66M. MIST’s [@Biotechnology] market capitalization is $126.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileMIST’s FA Score has 0 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • MIST’s FA Score: 0 green, 5 red.
According to our system of comparison, GYRE is a better buy in the long-term than MIST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 2 TA indicator(s) are bullish while MIST’s TA Score has 3 bullish TA indicator(s).

  • GYRE’s TA Score: 2 bullish, 4 bearish.
  • MIST’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than MIST.

Price Growth

GYRE (@Biotechnology) experienced а -6.70% price change this week, while MIST (@Biotechnology) price change was +7.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.06%. For the same industry, the average monthly price growth was +18.20%, and the average quarterly price growth was +35.38%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

MIST is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($644M) has a higher market cap than MIST($127M). MIST YTD gains are higher at: -36.864 vs. GYRE (-41.322). GYRE has higher annual earnings (EBITDA): 12.1M vs. MIST (-48.18M). MIST has more cash in the bank: 56M vs. GYRE (29.9M). GYRE has less debt than MIST: GYRE (1.59M) vs MIST (55.6M). GYRE has higher revenues than MIST: GYRE (101M) vs MIST (0).
GYREMISTGYRE / MIST
Capitalization644M127M507%
EBITDA12.1M-48.18M-25%
Gain YTD-41.322-36.864112%
P/E Ratio355.00N/A-
Revenue101M0-
Total Cash29.9M56M53%
Total Debt1.59M55.6M3%
FUNDAMENTALS RATINGS
GYRE vs MIST: Fundamental Ratings
GYRE
MIST
OUTLOOK RATING
1..100
664
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
63100
PRICE GROWTH RATING
1..100
7090
P/E GROWTH RATING
1..100
8100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIST's Valuation (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for GYRE (93) in the null industry. This means that MIST’s stock grew somewhat faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (95) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew similarly to MIST’s over the last 12 months.

GYRE's SMR Rating (63) in the null industry is somewhat better than the same rating for MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew somewhat faster than MIST’s over the last 12 months.

GYRE's Price Growth Rating (70) in the null industry is in the same range as MIST (90) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew similarly to MIST’s over the last 12 months.

GYRE's P/E Growth Rating (8) in the null industry is significantly better than the same rating for MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew significantly faster than MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYREMIST
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 20 days ago
81%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOCFF223.2515.75
+7.59%
Hochtief AG
IIDDY6.410.43
+7.19%
IGO Ltd
CRMZ2.400.02
+1.05%
CreditRiskMonitor.com, Inc.
IMXCF1.10N/A
N/A
IMAX China Hldg Inc
CRTUF10.92N/A
N/A
Cartica Acquisition Corp.

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been closely correlated with SPHDF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GYRE jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-1.66%
SPHDF - GYRE
82%
Closely correlated
N/A
BEAM - GYRE
42%
Loosely correlated
+1.35%
SPRC - GYRE
38%
Loosely correlated
+5.97%
AURA - GYRE
38%
Loosely correlated
+0.89%
CRBU - GYRE
37%
Loosely correlated
+0.98%
More

MIST and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIST has been loosely correlated with EQ. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then EQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIST
1D Price
Change %
MIST100%
-5.70%
EQ - MIST
41%
Loosely correlated
-0.24%
KRYS - MIST
36%
Loosely correlated
+0.41%
JBPHF - MIST
31%
Poorly correlated
N/A
GYRE - MIST
29%
Poorly correlated
-1.66%
OSRH - MIST
29%
Poorly correlated
+1.89%
More